Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Candesartan Cilexetil tablets USP 4 mg, 8 mg, 16 mg, and 32 mg. The drug is used to treat high blood pressure (hypertension) in adults and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
